We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
-5.2%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$176M
AUM Growth
-$3.89M
(-2.2%)
Cap. Flow
+$11.2M
Cap. Flow
% of AUM
6.35%
Top 10 Holdings %
Top 10 Hldgs %
22.1%
Holding
256
New
24
Increased
39
Reduced
133
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
WBA
Walgreens Boots Alliance
WBA
|
+$3.86M |
| 2 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$3.65M |
| 3 |
TSVT
2seventy bio
TSVT
|
+$3.13M |
| 4 |
uniQure
QURE
|
+$3.1M |
| 5 |
Embecta
EMBC
|
+$2.13M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AdaptHealth
AHCO
|
+$3.44M |
| 2 |
Elanco Animal Health
ELAN
|
+$2.97M |
| 3 |
Centene
CNC
|
+$2.7M |
| 4 |
iShares MBS ETF
MBB
|
+$2.05M |
| 5 |
Lantheus
LNTH
|
+$1.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 61.71% |
| 2 | Real Estate | 10.29% |
| 3 | Financials | 3.55% |
| 4 | Technology | 3.29% |
| 5 | Energy | 2.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Collegium Pharmaceutical
COLL
$1.17B
| $1.11M | 0.63% |
49,500
| – | – |
|
52
Intuitive Surgical
ISRG
$122B
| $1.1M | 0.62% |
3,750
-1,250
| -25% | -$390K |
|
53
Ultragenyx Pharmaceutical
RARE
$2.88B
| $1.07M | 0.61% |
30,000
+1,500
| +5% | +$59.4K |
|
|
RWT
54
Redwood Trust
RWT
$641M
| $1.05M | 0.59% |
146,593
| – | – |
|
55
Acadia Pharmaceuticals
ACAD
$4.38B
| $1.04M | 0.59% |
50,000
| – | – |
|
|
PETQ
56
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $1.02M | 0.58% |
52,000
-43,000
| -45% | -$769K |
|
57
AeroVironment
AVAV
$7.2B
| $1M | 0.57% |
9,000
-1,000
| -10% | -$101K |
|
|
IMGN
58
DELISTED
Immunogen Inc
IMGN
| $992K | 0.56% |
+62,500
| New | +$1.04M |
|
59
Procept Biorobotics
PRCT
$1.09B
| $984K | 0.56% |
30,000
-20,000
| -40% | -$682K |
|
60
Synopsys
SNPS
$73.6B
| $964K | 0.55% |
2,100
-400
| -16% | -$179K |
|
61
ADC Therapeutics
ADCT
$172M
| $958K | 0.54% |
1,068,468
+290,468
| +37% | +$386K |
|
62
Accuray
ARAY
$30.8M
| $952K | 0.54% |
350,000
| – | – |
|
63
Stereotaxis
STXS
$154M
| $948K | 0.54% |
600,000
+50,000
| +9% | +$80K |
|
64
Allient
ALNT
$1.49B
| $928K | 0.53% |
30,000
| – | – |
|
|
VRNA
65
DELISTED
Verona Pharma
VRNA
| $913K | 0.52% |
56,000
+1,000
| +2% | +$19.3K |
|
|
SCPH
66
DELISTED
scPharmaceuticals
SCPH
| $890K | 0.5% |
+125,000
| New | +$985K |
|
67
Arcutis Biotherapeutics
ARQT
$3.56B
| $876K | 0.5% |
165,000
-127,500
| -44% | -$1.08M |
|
68
Symbotic
SYM
$5.25B
| $836K | 0.47% |
25,000
| – | – |
|
69
Mobileye
MBLY
$7.76B
| $831K | 0.47% |
20,000
-5,000
| -20% | -$192K |
|
70
AGNC Investment
AGNC
$12.9B
| $799K | 0.45% |
84,646
-40,000
| -32% | -$396K |
|
71
Teradyne
TER
$50.5B
| $753K | 0.43% |
+7,500
| New | +$791K |
|
|
ONIT
72
Onity Group
ONIT
$344M
| $730K | 0.41% |
28,195
| – | – |
|
73
Protagonist Therapeutics
PTGX
$9.06B
| $726K | 0.41% |
+43,500
| New | +$844K |
|
74
Omnicell
OMCL
$2.09B
| $676K | 0.38% |
15,000
| – | – |
|
75
Helix Energy Solutions
HLX
$1.41B
| $670K | 0.38% |
+60,000
| New | +$578K |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q3 2023 Portfolio in Review
As of Q3 2023, AlphaCentric Advisors held 256 positions worth $176M, down 2.2% from $180M the previous quarter. Its ten largest holdings account for 22% of the portfolio.
AlphaCentric Advisors deployed $11.2M of net new capital in Q3 2023, opening 24 new positions and adding to 39 existing holdings. Its largest new stake was Revance Therapeutics, Inc.: 190,000 shares worth $2.18M.
By sector, the portfolio is most concentrated in Healthcare at 62% of assets, up from 60% a quarter earlier, followed by Real Estate and Financials.
On the sell side, the largest reduction was Jazz Pharmaceuticals, an estimated $1.9M trimmed.
- AlphaCentric Advisors's largest Q3 2023 buy was Revance Therapeutics, Inc.: 190,000 shares worth $2.18M.
- AlphaCentric Advisors added most to Walgreens Boots Alliance in Q3 2023, an estimated $3.86M increase.
- AlphaCentric Advisors's biggest Q3 2023 reduction was Jazz Pharmaceuticals, cutting an estimated $1.9M.
- AlphaCentric Advisors fully exited AdaptHealth in Q3 2023, selling an estimated $3.44M.
- AlphaCentric Advisors's ten largest holdings make up 22% of its $176M portfolio in Q3 2023.
- AlphaCentric Advisors opened 24 new positions and closed 21 in Q3 2023.
- AlphaCentric Advisors's portfolio value fell 2.2% quarter-over-quarter to $176M.
Based on AlphaCentric Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.